Spotlight Innovation Inc  

(Public, OTCMKTS:STLT)   Watch this stock  
Find more results for OTC:AEXP
+0.001 (0.37%)
Aug 18 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.11 - 0.14
52 week 0.10 - 1.75
Open 0.12
Vol / Avg. 13,245.00/22,382.00
Mkt cap 4.65M
P/E     -
Div/yield     -
EPS -0.74
Shares 32.94M
Beta 20.11
Inst. own 0%

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -101.61% -212.97%
Return on average equity - -
CDP Score - -


11147 Aurora Ave Bldg 3
URBANDALE, IA 50322-7904
United States - Map
+1-515-2749087 (Phone)

Website links


Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex.

Officers and directors

John Michael Krohn Chairman of the Board, President, Interim Chief Executive Officer, Chief Operating Officer
John William Pim CPA Chief Financial Officer
Age: 62
Sanjeev Agarwal Director
Age: 58
Ralph Arthur Director
Age: 69
June Beetler Director
Craig A. Lang Director
Age: 60